Evidence map›Paper›PMID 26624009›Full record

ArticlePloS one2015

Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice.

Danique van Vliet, Vibeke M Bruinenberg, Priscila N Mazzola, Martijn H J R van Faassen, Pim de Blaauw, Ido P Kema, M Rebecca Heiner-Fokkema, Rogier D van Anholt, Eddy A van der Zee, Francjan J van Spronsen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Current state of the treatment landscape of phenylketonuria.Orphanet journal of rare diseases · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Phenylketonuria.Nature reviews. Disease primers · 2021
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Danique van VlietUniversity of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Groningen, The Netherlands.
Vibeke M BruinenbergUniversity of Groningen, Center of Behavior and Neurosciences, Department of Molecular Neurobiology, Groningen, The Netherlands.
Priscila N MazzolaUniversity of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Groningen, The Netherlands.
Martijn H J R van FaassenUniversity of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, Groningen, The Netherlands.
Pim de BlaauwUniversity of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, Groningen, The Netherlands.
Ido P KemaUniversity of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, Groningen, The Netherlands.
M Rebecca Heiner-FokkemaUniversity of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, Groningen, The Netherlands.
Rogier D van AnholtIndependent Researcher, Deventer, The Netherlands.
Eddy A van der ZeeUniversity of Groningen, Center of Behavior and Neurosciences, Department of Molecular Neurobiology, Groningen, The Netherlands.
Francjan J van SpronsenUniversity of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Groningen, The Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NLDeventer Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPhenylketonuria (PKU) was the first disorder in which severe neurocognitive dysfunction could be prevented by dietary treatment. However, despite this effect, neuropsychological outcome in PKU still remains suboptimal and the phenylalanine-restricted diet is very demanding. To improve neuropsychological outcome and relieve the dietary restrictions for PKU patients, supplementation of large neutral amino acids (LNAA) is suggested as alternative treatment strategy that might correct all brain biochemical disturbances caused by high blood phenylalanine, and thereby improve neurocognitive functioning.

objectiveAs a proof-of-principle, this study aimed to investigate all hypothesized biochemical treatment objectives of LNAA supplementation (normalizing brain phenylalanine, non-phenylalanine LNAA, and monoaminergic neurotransmitter concentrations) in PKU mice.

methodsC57Bl/6 Pah-enu2 (PKU) mice and wild-type mice received a LNAA supplemented diet, an isonitrogenic/isocaloric high-protein control diet, or normal chow. After six weeks of dietary treatment, blood and brain amino acid and monoaminergic neurotransmitter concentrations were assessed.

resultsIn PKU mice, the investigated LNAA supplementation regimen significantly reduced blood and brain phenylalanine concentrations by 33% and 26%, respectively, compared to normal chow (p<0.01), while alleviating brain deficiencies of some but not all supplemented LNAA. Moreover, LNAA supplementation in PKU mice significantly increased brain serotonin and norepinephrine concentrations from 35% to 71% and from 57% to 86% of wild-type concentrations (p<0.01), respectively, but not brain dopamine concentrations (p = 0.307).

conclusionsThis study shows that LNAA supplementation without dietary phenylalanine restriction in PKU mice improves brain biochemistry through all three hypothesized biochemical mechanisms. Thereby, these data provide proof-of-concept for LNAA supplementation as a valuable alternative dietary treatment strategy in PKU. Based on these results, LNAA treatment should be further optimized for clinical application with regard to the composition and dose of the LNAA supplement, taking into account all three working mechanisms of LNAA treatment.

Indexed as

Dietary SupplementsAmino Acids, NeutralAnimalsBrainDisease Models, AnimalDopamineFemaleMaleMiceNeurocognitive DisordersPhenylalaninePhenylketonuriasSerotoninAmino Acids, NeutralDopaminePhenylalanineSerotonin

Identifiers

PMID26624009
PMCPMC4666635
OpenAlexW2182690820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.